Anti-GD2 Antibody Infusion Without IL-2 for Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for GD2 positive cancers using anti-GD2 antibodies often require concomitant administration of cytokines like IL-2, leading to severe side effects and adverse events.
Innovation Solution
Administering a preparation comprising a chimeric or humanized anti-GD2 antibody without IL-2, potentially without any cytokines, and using a continuous infusion for 24 hours, optionally preceded or followed by retinoid treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-GD2 antibody is administered with concomitant IL-2 treatment, then therapeutic efficacy is enhanced, but severe side effects and adverse events occur
Solution Approach 1:
The patent extracts and eliminates IL-2 from the treatment regimen, demonstrating that anti-GD2 antibody alone can achieve therapeutic efficacy without requiring concomitant IL-2 administration, thereby removing the source of severe side effects while maintaining treatment effectiveness
Solution Approach 2:
The patent changes the treatment parameter by administering anti-GD2 antibody as a continuous infusion over 24 hours rather than intermittent dosing, which modifies the pharmacokinetic profile to maintain therapeutic efficacy while reducing the need for IL-2 and associated toxicity
2Reliability
If anti-GD2 antibody is administered as continuous infusion for 24 hours, then therapeutic efficacy is maintained, but treatment duration increases
Solution Approach 1:
The patent implements continuous infusion of anti-GD2 antibody for 24 hours to maintain steady therapeutic levels in the patient, ensuring consistent antitumor activity throughout the treatment period rather than relying on peak concentrations from intermittent dosing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces adverse effects and maintains therapeutic efficacy by eliminating the need for cytokines, thereby minimizing side effects such as pain and other severe reactions.
Implementation Method 1
The fused IL-2 then stimulates the patient's immune system against the tumor by activation of both, NK and T cells, whereas the Fc portion of the antibody is designed to trigger tumor cell killing by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Implementation Method 2
The Fc portion of the antibody is designed to trigger tumor cell killing by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Data Source
AI summary
The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2) wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.